FDA approves daraxonrasib for metastatic pancreatic cancer treatment

The FDA has approved the drug Rasonque (daraxonrasib) for patients with metastatic pancreatic cancer who have failed prior systemic therapy. Phase III clinical trial data indicates the drug nearly doubles median survival time compared to standard chemotherapy, marking a significant therapeutic advancement for this aggressive malignancy.